Tag: vaccine for kids

  • Sources and updates, June 26

    Sources and updates, June 26

    A new chart from the CDC shows booster shot eligibility and uptake by age. Retrieved on June 26.
    • CDC report on Paxlovid distribution: A major study from the CDC’s Morbidity and Mortality Weekly Report this week: researchers at the CDC and collaborators studied the distributions of antiviral COVID-19 drugs Paxlovid and Lagevrio (also called Molnupiravir) by ZIP code, comparing ZIP codes with the CDC’s Social Vulnerability Index. More than one million prescriptions were dispensed between late December 2021 and late May 2022, the study found. But, by the end of that period, prescription rates were twice as high in low- and medium-vulnerability ZIP codes as in high-vulnerabilty ZIP codes—indicating that these antivirals are not reaching the people who most need them.
    • CDC booster shot data update: The CDC has added a new chart to its “COVID-19 Vaccinations in the United States” page, showing booster shot eligibility and uptake by age. The chart includes two rounds of boosters for seniors; according to the data, 64% of eligible seniors have received their first booster, but only 21% have received their second booster. The data are also available for download.
    • COVID-19 vaccinations among children: I also recently learned about this CDC page focused on kids’ vaccinations, including vaccination coverage by demographic factors such as poverty status, parents’ education level, and insurance. The data come from a national survey previously used to monitor flu vaccinations among children. Data are updated monthly, and don’t yet include figures for children under 5; but existing data for children ages 5-17 affirm that vaccine uptake for kids has been low so far.
    • Guide to finding government COVID-19 documents: The Digital Public Library of America has released a free ebook with an archive of over 3,000 government documents related to the pandemic response. These documents were collected by the COVID Tracking Project during its year of work, and have been meticulously categorized and indexed in true CTP fashion. CTP alum Jennifer Clyde was the project’s editor.
    • Commonwealth Fund report on improving our public health system: A new report from healthcare-focused foundation The Commonwealth Fund provides recommendations for improving the country’s public health system. It focuses on organizing local agencies, providing more funding, improving trust, and other key topics.
    • History of exposure notification apps: Jenny Wanger, whom I interviewed about COVID-19 exposure notification apps back in spring 2021, sent me this paper she wrote about the technology, which was published earlier in June. The paper provides a report of how exposure notification protocols were developed, how states used the technology, and how limited data made it difficult to assess the technology’s success.

  • Sources and updates, June 19

    Sources and updates, June 19

    • Curative provides testing trends and commentary to reporters: Last week, I talked to Isaac Turner, chief technology officer at Curative, a COVID-19 testing company with more than 15,000 locations across the country. Curative staff keep a close eye on trends in test positivity and cycle threshold values (a measure of how infectious someone with COVID-19 may be), and share this information with health agencies. While the company doesn’t have a public dashboard, they’re eager to share data with reporters on request and discuss testing trends. For example, Turner told me that in recent weeks, there has been “almost no surge in testing” even though COVID-19 cases have clearly risen across the country. To reach out, you can contact PIO Alana at alana.prisco@ketchum.com.
    • Walgreens COVID-19 testing dashboard: Another source for testing trends, as government sources become less reliable, is the Walgreens dashboard—incorporating data from COVID-19 PCR testing at more than 5,000 Walgreens locations across the country. In partnership with Aegis Services, many of these test samples are sequenced or identified as specific variants via S-gene target failure. The Walgreens dashboard has a shorter lag time than the CDC’s variant prevalence estimates, so it may be a useful way to see trends in advance.
    • Kids under 5 can finally get vaccinated: As of yesterday, the CDC has formally recommended versions of both Pfizer’s and Moderna’s COVID-19 vaccines for children under age 5 after they received emergency use authorization from the FDA. This youngest age group can finally get vaccinated! I usually like to watch the FDA advisory committee meetings where new vaccines are discussed, but didn’t have the bandwidth to watch or report on the meetings this week; if you’d like to read up on them, I recommend the Your Local Epidemiologist and STAT News recaps.
    • Estimating lives saved by universal healthcare: A major new paper this week, by researchers at the Yale School of Public Health, estimates that if the U.S. had a single-payer universal healthcare system, the country may have saved 212,000 lives during the first year of the pandemic. They arrived at this estimate by analyzing data on Americans who lost their health insurance in 2020 or were already uninsured, combined with the impact of being uninsured on COVID-19 mortality. A universal healthcare system would have also saved over $100 billion in healthcare costs in 2020, the researchers found. Read more at Scientific American.
    • Long COVID may be less likely after an Omicron case: Another new study that caught my attention this week: researchers at King’s College London used the U.K.’s excellent statistics on Long COVID prevalence to compare the risks of long-term symptoms after a Delta infection to the risks after an Omicron infection. They found that the risk of Long COVID after an Omicron infection was about half the risk after a Delta infection, which is potentially pretty good news! Still, it’s still concerning that so many people are at risk for Long COVID after an Omicron infection considering the high case numbers driven by this variant, some outside researchers told NPR.
    • CDC study on COVID-19 risk for people with disabilities: And one more notable study: CDC researchers examined COVID-19 hospitalization rates among Medicare beneficiaries, comparing those who were on this healthcare plan due to disability to those on the plan due to age. They found that disability beneficiaries had 50% higher hospitalization rates, with the risk for hospitalization increasing with age in both groups. Also: Native American Medicare beneficiaries had the highest hospitalization rate of any racial or ethnic group.

  • Sources and updates, May 29

    • New Surgeon General advisory on health worker burnout: This week, U.S. Surgeon General Dr. Vivek Murthy released a new advisory on COVID-19 burnout among health workers, summarizing research on the issue and highlighting it as a public health priority. The advisory discusses a variety of societal, cultural, structural, and organizational factors contributing to health worker burnout, while tying this burnout to growing shortages of doctors and other health professionals. From the one-page summary of the advisory: “If not addressed, the health worker burnout crisis will make it harder for patients to get care when they need it, cause health costs to rise, hinder our ability to prepare for the next public health emergency, and worsen health disparities.”
    • CDC may change COVID-19 reporting for hospitals: The CDC is planning a few changes to its reporting requirements for hospitals in order to simplify the reporting process and cut down on redundant information, according to a draft plan shared with Bloomberg. Among the changes: hospitals may no longer be required to report suspected COVID-19 cases (i.e. those cases not yet confirmed with a PCR test); with most hospitals testing all patients when they’re admitted, suspected cases are less common and the data are less useful than they had been at earlier points in the pandemic. The CDC may also stop requiring COVID-19 reporting from some types of facilities, such as mental health centers, and may change the frequency of required reporting.
    • New preprint about Omicron BA.4 and BA.5: While the U.S. mostly worries about BA.2.12.1, additional Omicron subvariants BA.4 and BA.5 have been spreading in South Africa and other countries. A new study from a highly-regarded consortium of Japanese researchers suggests that BA.4 and BA.5 are about 20% more transmissible than BA.2 (similarly to BA.2.12.1). Also, even more concerning: the researchers found that BA.4 and BA.5 are more capable of resisting protection from a prior Omicron infection than BA.1. While the study has not yet been peer-reviewed, it garnered a lot of attention on Twitter this week from scientists warning that we need to watch out for these subvariants.
    • U.S. gets closer to a vaccine for kids under five: The FDA has set new dates for its vaccine advisory committee to review data on COVID-19 vaccines for children under age five: the committee will discuss both Moderna’s and Pfizer’s under-five vaccines on June 15, after discussing Moderna’s vaccine for children ages six to 17 on June 14. This announcement came after Pfizer and BioNTech released new data on their under-five vaccine, saying that a series of three doses provided strong protection against severe disease. There are some caveats for the data (which were shared via press release), but this is great news for children under age five and their families.
    • NIH sharing some COVID-19 technology (but not patents): I missed this news from earlier in May: the National Institutes of Health has made a deal with the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool to lisense 11 technologies used in COVID-19 vaccines and therapeutics. This lisense will allow pharmaceutical manufacturers around the world to make the coronavirus spike protein, RNA virus tests, and other COVID-19 components, increasing access to these technologies in low- and middle-income countries. Of course, it would be better for these countries if the NIH had shared full vaccine patents, but apparently that’s asking too much.

  • Sources and updates, May 15

    • COVID-19 deaths that could’ve been prevented with vaccines: A new analysis from the Brown University School of Public Health suggests that almost 319,000 U.S. COVID-19 deaths could have been avoided if all adults had gotten vaccinated against the disease. This number differs significantly by state; there were 29,000 preventable COVID-19 deaths in Florida, compared to under 300 in Vermont. For more context on the analysis, see this article in NPR.
    • CDC dashboard in Spanish: The CDC has translated its COVID-19 Data Tracker into Español. At a glance, the Spanish version appears to include all the major aspects of the tracker: cases, deaths, vaccinations, community transmission, variant prevalence, wastewater, etc. Of course, it would have been great if the agency could’ve devoted resources to this translation effort well below spring 2022, when the number of people looking to the agency for COVID-19 guidance is pretty low.
    • CDC may lose access to COVID-19 data: According to reporting from POLITICO, the CDC and other national health agencies may no longer have the authority to require COVID-19 data reporting from states and individual health institutions if the Biden administration allows the country’s federal pandemic health emergency to end this summer. Such a change in authority could lead to the CDC (and numerous other researchers across the country) losing standardized datasets for COVID-19 hospitalizations, transmission in nursing homes, PCR testing, and other key metrics. Considering that hospitalizations are considered the most reliable metric right now, this could be a major blow.
    • COVID-19 testing declines globally: Speaking of losing reliable data: this report from the Associated Press caught my eye. The story, by Laura Ungar, explains that the U.S. is not the only country to see a major decrease in reported COVID-19 tests (a.k.a. Lab-based PCR, not at-home rapid tests) in recent months. “Experts say testing has dropped by 70 to 90% worldwide from the first to the second quarter of this year,” Ungar writes, “the opposite of what they say should be happening with new omicron variants on the rise in places such as the United States and South Africa.”
    • More promising data on Moderna kids’ vaccine: While Pfizer’s vaccine for children under five remains in development, Moderna continues to release data suggesting that this company is further ahead in providing protection for the youngest age group. This week, Moderna announced a half-dose of its vaccine provides a “strong immune response” in children ages six to 11; the announcement was backed up by a scientific study published in the New England Journal of Medicine (so, more rigorous than your typical press release). The FDA is currently evaluating a version of Moderna’s vaccine for children between ages six months and six years.

  • Sources and updates, May 8

    • CDC adds second boosters to its vaccine dashboard: In the latest update to the CDC’s COVID Data Tracker, you can now find a national tally of Americans who have received second booster shots on the “COVID-19 Vaccinations in the United States” page. About 10 million people have received these additional shots as May 6, about one-tenth the number of first booster recipients. The CDC has yet to add state-by-state or demographic data for second boosters.
    • KFF updates COVID-19 Vaccine Monitor: This week, the Kaiser Family Foundation published the latest update of its Vaccine Monitor, a long-running project tracking Americans’ attitudes towards COVID-19 vaccines and related issues. One notable finding from the April update: just 18% of parents with children under age five are “eager to get their child vaccinated right away,” compared to 27% who say they will “definitely not” get their child vaccinated. This report also includes survey findings on mask-wearing, COVID-19 in the workplace and in schools, and future booster shots.
    • Biobot on GitHub: I recently learned that Biobot Analytics, the leading COVID-19 wastewater surveillance company, publishes its underlying data on GitHub. This repository includes coronavirus concentrations in wastewater treatment plants monitored by Biobot across the country, along with regional wastewater data, national data, and COVID-19 case numbers for comparison.
    • TON’s Guide to Tracking Source Diversity: Not directly COVID-related, but a resource that I thought readers may find useful: The Open Notebook (TON) has published a detailed guide for journalists seeking to track the diversity of sources interviewed for their stories. While TON is geared towards science writers, this guide is broadly applicable to any reporter who spends a lot of time seeking out and talking to experts.

  • Sources and updates, April 17

    • A Poor People’s Pandemic Report: This new report, compiled by the Poor People’s Campaign (a national activist group that advocates for low-income Americans) as well as U.N. economists and other researchers, shows the pandemic’s disproportionate impacts by income levels. Overall, people in poorer counties died of COVID-19 at nearly twice the rate of those in richer counties, the report found. On this dashboard, users can see the correlations of COVID-19 death rates with income, population density, and other factors. This article from the Guardian includes more context on the findings.
    • SARS-CoV-2 in Animals: I recently learned about this dashboard while working on an upcoming Documenting COVID-19 story: the U.S. Department of Agriculture (USDA) reports on COVID-19 cases in animals, identified through both PCR and antibody tests. In addition to the case numbers, the dashboard includes announcements of notable cases and recent research in this area. It’s important to note that these numbers are likely undercounts, because the U.S. doesn’t actively monitor animals for COVID-19, unlike some other countries.
    • The Role of Wastewater Data in Pandemic Management: This new report from the Rockefeller Foundation examines how state and local public health agencies are using wastewater surveillance. The foundation surveyed 12 state and 194 local agencies, many of which have been monitoring wastewater for a year or more; this report includes findings on the populations served by wastewater surveillance, data used to make pandemic management decisions, barriers that agencies face for expanding their surveillance, and more.
    • GAO report on Wastewater Surveillance: Speaking of wastewater, the U.S. Government Accountability Office (GAO) also released a report on the monitoring tool this week. The GAO report provides an overview of how wastewater surveillance works and its potential for providing early warnings of outbreaks, along with challenges faced by agencies seeking to start testing their wastewater. From the report’s highlights: “the lack of national coordination and standardized methods pose challenges to wider adoption.”
    • Protection from vaccination and previous infection: A new study, published in the CDC MMWR this week, assesses the benefits of COVID-19 vaccination for people who had a prior infection. During the Omicron surge, the study shows, people who had been previously infected and vaccinated were less likely to be hospitalized due to a COVID-19 reinfection, compared to those who weren’t vaccinated. Vaccine effectiveness against hospitalization was 35% for those who had two doses, and 69% for those who had received a booster.
    • Pfizer seeks booster shot for 5-11 year olds: This week, Pfizer announced that it’s asking the FDA to authorize a booster shot for children in the 5 to 11 age group. The company cited new data showing that kids who got a booster shot six months after their primary series experienced a significant increase in antibodies that protect against COVID-19. These data have yet to be published in a scientific report or vetted by experts, though. Also, still no news on Pfizer’s vaccine for younger children (which could also require three doses).

  • Sources and updates, March 27

    • New report on pandemic-related workplace violence for public health officials: A new study, published last week in the American Journal of Public Health, shares the results of a survey that included hundreds of public health officials across the U.S. During the study’s time frame (March 2020 to January 2021), the researchers identified about 1,500 instances of harassment against public health officials, and found that over 200 officials left their jobs. And public health has only become more polarized in the year since this survey period ended. See this article in STAT News for more context on the study.
    • Health insurance plans available through the federal insurance marketplace: This one isn’t directly COVID-related, but it seemed like an interesting data source to share: the Centers for Medicare & Medicaid Services (CMS) publishes a series of data files on health insurance plans available through the federal Health Insurance Exchange. The files include health benefits, coverage limits, cost-sharing potential, provider networks, anonymized insurance claims, and much more. (H/t Data Is Plural.)
    • At-home COVID-19 test use exacerbates inequities: This week, the CDC published a new MMWR study discussing rapid at-home test use. The authors used an online survey to estimate at-home test use among about 400,000 U.S. adults between August 2021 and early March 2022. Its findings provide additional evidence for the popularity of these tests during the Omicron surge, as well as for the way that these tests exacerbate health inequities in the U.S.: “at-home test use was lower among persons who self-identified as Black, were aged ≥75 years, had lower incomes, and had a high school level education or less,” the authors reported.
    • Considering another round of mRNA booster shots: Will the U.S. authorize a fourth round of shots for Americans who received the Pfizer and Moderna vaccines? At the moment, signs point to yes: countries like Israel and the U.K., which U.S. regulators watch for their vaccine efficacy data, are providing fourth doses to seniors. And the Biden administration is planning fourth doses for U.S. adults over age 50, the New York Times reported on Friday. Data so far suggest that these additional doses may be useful for older adults, but provide less of an immunity boost in younger age groups; Dr. Katelyn Jetelina’s Your Local Epidemiologist post on the subject provides a helpful overview of the evidence.
    • New data on Moderna vaccine for young children: As we consider additional boosters for seniors, the youngest Americans may soon be eligible for vaccination! Finally! After a lot of back-and-forth on the potential of Pfizer’s vaccine for kids under age five, Moderna released data this week suggesting that the company has found a dosage of its vaccine that significantly reduces the risk of severe COVID-19 symptoms for children between six months and six years old. Effectiveness against any symptomatic coronavirus infection was only about 40% in this trial—but that result is in line with vaccine efficacy for adults during the Omicron wave, when Moderna’s trial was conducted.

  • National numbers, February 13

    National numbers, February 13

    Current COVID-19 hospitalizations in the U.S. have fallen under 100,000 for the first time since the Omicron surge started. Chart by Conor Kelly, posted on Twitter on February 9.

    In the past week (February 5 through 11), the U.S. reported about 1.5 million new COVID-19 cases, according to the CDC. This amounts to:

    • An average of 215,000 new cases each day
    • 459 total new cases for every 100,000 Americans
    • One in 218 Americans testing positive for COVID-19
    • 43% fewer new cases than last week (January 29-February 4)

    Last week, America also saw:

    • 85,000 new COVID-19 patients admitted to hospitals (26 for every 100,000 people)
    • 16,000 new COVID-19 deaths (4.9 for every 100,000 people)
    • 100% of new cases are Omicron-caused (as of February 5)
    • An average of 300,000 vaccinations per day (per Bloomberg)

    COVID-19 cases continue to decline across the U.S. as the country comes out of its Omicron surge. Nationwide, the U.S. reported an average of 215,000 new cases a day last week—a drop of about 75% from the peak of the Omicron surge, when nearly 800,000 new cases were reported each day.

    Hospitalizations are also decreasing: this week, the number of confirmed and suspected COVID-19 patients in U.S. hospitals dropped under 100,000 for the first time since the surge started in December. Deaths are decreasing as well, but are still at high levels: over 2,000 Americans are dying of COVID-19 each day.

    All 50 states and the majority of counties continue to report case declines, according to the latest Community Profile Report. But case rates are still very high across the country, well above the CDC’s threshold for high transmission (more on this later in the issue).

    States with high case rates this week include Alaska, Kentucky, West Virginia, Montana, Mississippi, North Dakota, California, and Idaho; all reported over 700 new cases for every 100,000 residents in the week ending February 9.

    Omicron is still causing 100% of new cases in the country, according to CDC estimates. But the agency is now splitting its estimates into the original Omicron and its sister strain BA.2: BA.2 caused between 2% and 7% of new cases nationwide in the week ending February 5, the CDC says. In the coming weeks, we’ll see whether this strain—which is even more transmissible than original Omicron—has an impact on U.S. case numbers.

    New vaccination numbers have been fairly low for the past couple of weeks, with an average of under 300,000 shots given each day (including boosters). And the FDA is now delaying vaccine authorization for children under age 5: the agency has decided to wait for Pfizer to provide data on how well a three-dose series performs in this age group, after initially considering authorization based on data about two doses.

  • National numbers, February 6

    National numbers, February 6

    COVID-19 cases are now on the decline almost everywhere in the U.S. (right), though they are still incredibly high throughout the country (left). Note that Tennessee appears (incorrectly) green on the left because of a data error. Chart from the February 3 Community Profile Report.

    In the past week (January 29 through February 4), the U.S. reported about 2.6 million new cases, according to the CDC. This amounts to:

    • An average of 378,000 new cases each day
    • 806 total new cases for every 100,000 Americans
    • One in 124 Americans testing positive for COVID-19
    • 38% fewer new cases than last week (January 22-28)

    Last week, America also saw:

    • 112,000 new COVID-19 patients admitted to hospitals (34 for every 100,000 people)
    • 17,000 new COVID-19 deaths (5.1 for every 100,000 people)
    • 100% of new cases are Omicron-caused (as of January 29)
    • An average of 300,000 vaccinations per day (per Bloomberg)

    Nationwide, new COVID-19 case numbers have decreased for the third week in a row. The country reported an average of 378,000 new cases each day last week—about half the daily case number reported at the peak of the Omicron surge three weeks ago.

    Hospitalizations are also decreasing, with the HHS reporting about 115,000 inpatient beds used for COVID-19 patients as of February 5—down from a peak of over 150,000. Still, hospitals across the country continue to be overwhelmed as they deal with staffing shortages and limited drugs that work against Omicron compared to past variants.

    National COVID-19 deaths passed 900,000 this week, according to the New York Times and other trackers. More than 2,000 Americans are dying of COVID-19 every day, and this trend is likely to continue as the Omicron surge wanes; as always, patterns in death data follow patterns in case data by several weeks.

    New case rates are dropping in all 50 states and almost all territories, according to the latest Community Profile Report. States with the highest case rates this week include Alaska, North Dakota, Washington, West Virginia, Wyoming, and Tennessee: all reported at or above 1,200 new cases for every 100,000 people in the week ending February 2.

    Remember, even though cases are going down, many parts of the country are still seeing far higher numbers than they did in previous surges. Even in New York City, now about a month past the peak of its Omicron surge, the city health department reported about 220 new cases for every 100,000 people last week—more than double the CDC threshold for high transmission. It’s important that we remain cautious until the numbers are truly low.

    As Omicron continues to spread—and as the U.S. reported record cases in children this past January—Pfizer has announced it plans to ask the FDA to authorize its vaccine for children under age 5. The problem is: Pfizer’s clinical trial data have, so far, demonstrated that a two-dose vaccine series with a very small dosage is effective in the youngest kids (6 months to 2 years), but not in kids ages 2 to 5. COVID-19 experts are split on this rather complicated situation; you can find more details at Your Local Epidemiologist and at STAT News.

  • As Omicron hits schools, K-12 data void is wider than ever

    As Omicron hits schools, K-12 data void is wider than ever

    Two years into the pandemic, you might think that, by now, schools would have figured out a strategy to continue teaching kids while keeping them safe from the coronavirus. Instead, the school situation is more chaotic than ever—thanks to Omicron combined with staff shortages, pandemic fatigue, and other ongoing issues.

    Thousands of schools went online or closed entirely this week, likely more than in any other week since spring 2020. And yet: there is currently no national data source tracking COVID-19 cases in schools, and nine states fail to report any data on this crucial topic.

    This week, I had a story published in education outlet The Hechinger Report about the challenges that schools faced in staying open during the fall 2021 semester. For the story, I returned to the five school communities that I profiled last summer during my Opening project to see how they fared in the fall.

    The story identifies four major challenges:

    • Quarantines: When a school or district faces a COVID-19 outbreak, contact tracing for all of the cases can quickly become incredibly time-consuming. This work “can be very burdensome for the school and the health department,” pediatrician Leah Rowland told me—especially when a school doesn’t have its own school nurse.
    • Testing: Surveillance testing can help identify cases early, while test-to-stay programs can keep kids out of quarantine; in fact, the CDC recently endorsed test-to-stay, adding the strategy to its official schools guidance. But testing programs are costly and hard to set up; in absence of state-wide testing support, they tend to be implemented at larger and wealthier school districts.
    • Staff shortages: Every single school leader and expert I spoke to for the story named staff shortages as a major challenge. “[Potential staff] can work at McDonald’s, and have a whole lot less stress and make more money than working as an instructional assistant for Garrett County Public Schools,” Alison Sweitzer, director of finance at this Maryland district, told me.
    • Pandemic fatigue: In a lot of places around the U.S., schools are one of the only—if not the only—institution still enforcing COVID-19 policies, like masks and social distancing. This can drive up tension between parents and school staff; and school nurses, who act as public health experts within the school, often bear the brunt of the criticism. Robin Cogan, legislative co-chair for the New Jersey State School Nurses Association, told me that she’s never felt this exhausted, in 21 years of serving as a school nurse.
    • Low vaccination rates: As of this week, about one in four children ages five to 11 has received at least one dose of a COVID-19 vaccine. This ranges wildly by state, though, with 57% of children in this age group vaccinated in Vermont compared to under 20% in much of the South. Vaccinated students and staff don’t have to quarantine when they’re exposed to a COVID-19 case, but despite this strong motivator, the school leaders I spoke to have not seen much enthusiasm for the shots.

    I reported most of that Hechinger Report story before Omicron hit the U.S. But it’s clear to see how the new variant has exacerbated all of these challenges. As this super-contagious variant hits schools, cases are increasingly rapidly—leading to more quarantines and contact tracing pressures. School staff are getting sick, intensifying shortages. And the students and staff who are unvaccinated are the most vulnerable.

    “Pediatric hospitalizations are at the highest rate compared to any prior point in the pandemic,” CDC Director Dr. Rochelle Walensky said at a press briefing on Friday. The CDC is investigating whether this increase reflects an inherent severity of Omicron in children or whether it’s simply the product of record-high cases everywhere. Either way, though, the data clearly show that vaccination is the best way to protect children from severe COVID-19. For children under age five, Dr. Walensky said, “it’s critically important that we surround them with people who are vaccinated to provide them protection.”

    According to Burbio’s K-12 School Opening Tracker, 5,441 schools had disruptions in the week of January 2. Those disruptions include schools going online or canceling instruction entirely—anything caused by the pandemic, as opposed to by weather or some other reason. This is higher than any other week in the 2021-2022 school year by a long shot; the previous record was 2,846 disruptions in early November.

    New York City has been one of the U.S.’s first Omicron hotspots, and the variant has had a massive impact on the city school system. Case rates shot up in December, with almost 5,000 new cases reported by the city Department of Education (DOE) in the week ending December 26. This number, as well as January DOE data, is likely a massive undercount, though, because of the sheer number of cases being reported within the city right now.

    The PRESS NYC schools dashboard, which references DOE data, provides this caveat: “As we understand it, the Situation Room cannot keep up with cases coming in and many cases aren’t even making it into DOE data.”

    Stories from inside the public school system suggest that kids are going into classrooms just to sit in study hall and, very likely, infect each other. One Reddit post from a NYC high school student described the case numbers at their school shooting up from six total cases in mid-December, to 100 on January 3, to over 200 by the end of this week. The majority of those cases weren’t yet reflected in DOE data, the student said.

    Yet NYC’s new mayor, Eric Adams, seems determined to keep schools open at all costs.

    Other districts have also had their fair share of conflict this week. In Chicago, teachers are on strike for safer in-person conditions. The situation has led to classes getting canceled entirely, as the school district locked striking teachers out of their online accounts—preventing them from teaching remotely. And in many other districts, including Seattle and Washington D.C., the start of the spring semester was delayed as the district sought to test all students, teachers, and staff before reopening.

    With all of this tension in mind, I set out yesterday to update my K-12 school data annotations for the first time in several months. These annotations reflect the availability of data on COVID-19 cases and related metrics in school buildings, by state and at the national level.

    Here’s what I found:

    • 31 states and D.C. are reporting data on COVID-19 cases in K-12 school settings. There’s a lot of variability in this reporting, though, from states like Connecticut, which reports a detailed breakdown of cases by school (including downloadable historical data), to states like Maine, which only reports cases in “active outbreaks.”
    • 10 states are reporting what I categorize as “somewhat” cases in K-12 schools. This includes states like Arizona, which reports the number of schools with COVID-19 outbreaks by county (but no case numbers), and Illinois, which reports cases in school-aged children (but not cases that are school-specific).
    • Nine states are not reporting any K-12 school data. These states are: Alaska, California, Florida, Iowa, Kentucky, Nebraska, New Mexico, Oklahoma, and Wyoming. Note, both Florida and Kentucky used to report school data, but have discontinued this reporting since last school year.
    • New York continues to have the most complete school data, by my assessment, as it’s the only state to report both COVID-19 tests and school enrollment.
    • Six states are now reporting in-person school enrollment, a key metric needed to analyze COVID-19 data: Connecticut, Delaware, Hawaii, New York, Texas, and Utah.
    !function(){“use strict”;window.addEventListener(“message”,(function(e){if(void 0!==e.data[“datawrapper-height”]){var t=document.querySelectorAll(“iframe”);for(var a in e.data[“datawrapper-height”])for(var r=0;r<t.length;r++){if(t[r].contentWindow===e.source)t[r].style.height=e.data["datawrapper-height"][a]+"px"}}}))}();

    In short, while a lot of data on COVID-19 in schools are available from state public health departments, these data are wildly unstandardized and difficult to analyze holistically. See the annotations page for more details on your state.

    Meanwhile: at this time, there is no national data source on COVID-19 cases in schools. The federal government has never reported these data; the best that our federal health agencies can do, apparently, is compile rarely-updated dashboards of school learning modes (i.e. which districts are in-person vs. remote). Last school year, a couple of research projects sprung up to compile information from state agencies and other sources; but as of now, those projects are all discontinued.

    While a number of studies have demonstrated the effectiveness of common safety policies (masks, vaccinations, ventilation, etc.), many of the researchers who study school COVID-19 safety have to use small sample sizes, such as a single district or state. CDC researchers often rely on proxies like county case rates to analyze the impact of different policies. This research is a far cry from the work that we could do with a comprehensive, national dataset of COVID-19 cases in schools.

    Without detailed data on COVID-19 in schools, it’s difficult to make good policy decisions. The data void leaves space for pundits on both sides of the aisle: some can argue that schools are safe and must remain open in-person no matter how high community cases get, while others can argue that schools are incredibly dangerous and must close.

    The COVID-19 in schools data void is wider than ever right now, even though we need information desperately as Omicron spreads.

    More K-12 reporting